SR One Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

SR One Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.1M	Hold	4,012,903	–	–	3.09%	10
2026 Q1	$32.2M	Hold	4,012,903	–	–	3.52%	9
2025 Q4	$46.8M	Hold	4,012,903	–	–	6.62%	6
2025 Q3	$40.3M	Hold	4,012,903	–	–	5.83%	7
2025 Q2	$70M	Hold	4,012,903	–	–	15.18%	2
2025 Q1	$50.5M	Hold	4,012,903	–	–	12.97%	2
2024 Q4	$42.3M	Hold	4,012,903	–	–	10.32%	2
2024 Q3	$58.2M	Hold	4,012,903	–	–	11.67%	3
2024 Q2	$34.1M	Hold	4,012,903	–	–	10.69%	3
2024 Q1	$41M	Hold	4,012,903	–	–	11.26%	3
2023 Q4	$22M	Hold	4,012,903	–	–	9.23%	2
2023 Q3	$15.2M	Hold	4,012,903	–	–	7.77%	4
2023 Q2	$26.9M	Hold	4,012,903	–	–	11.59%	4
2023 Q1	$26.1M	Buy	4,012,903 +1,003,226	+33%	+$7.71M	9.73%	4
2022 Q4	$25.7M	Buy	+3,009,677	New	+$19.5M	9.37%	3

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SR One Capital Management's SPRY Position: Q2 2026 in Review

SR One Capital Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 4,012,903 shares worth $32.1M. The position accounts for 3.09% of the portfolio, ranked #10.

SR One Capital Management first reported a position in SPRY in Q4 2022 and has held it in 15 quarters since. The position peaked at $70M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

SR One Capital Management held 4,012,903 shares of ARS Pharmaceuticals worth $32.1M as of Q2 2026.
SR One Capital Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
ARS Pharmaceuticals made up 3.09% of SR One Capital Management's portfolio in Q2 2026, its #10 holding.
SR One Capital Management first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
SR One Capital Management's ARS Pharmaceuticals position peaked at $70M in Q2 2025.
208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.